Adults 18 to 65, any sex, with Human Immunodeficiency Virus or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Reaction Time Measured Using the Psychomotor Vigilance TaskPrimary· 1 day
The Psychomotor Vigilance Task (PVT) is commonly used to asses the impact of sleep (or sleep deprivation) on cognitive performance. Subjects are instructed to respond (by tapping a key on a keyboard) as fast as possible to a graphical stimulus displayed on a computer screen. The stimulus is presented multiple times at variable intervals every few seconds for 10 minutes. The reaction time is the mean latency from appearance of the stimulus to the response by the participant. Higher values suggest a slower reaction time compared to lower values.
Group
Value
95% CI
PLWH+OSA+High AT
346
± 38
PLWH+OSA+Low AT
353
± 39
PLWH-OSA
348
± 48
Reactive Hyperemia Index (RHI) Assessed by Peripheral Arterial TonometrySecondary· 1 day
Reactive hyperemia is measured using the commercially available EndoPAT device (Itamar Medical). Briefly, the device uses finger plethysmography to measure the finger arterial pulse wave amplitude. Subjects have the pulse wave measured during rest, during the application of a blood pressure cuff to occlude blood flow for 5 minutes, and then once the blood pressure cuff is deflated. The reactive hyperemia index (RHI) is the ratio (thus dimensionless) of the pulse wave amplitude after occlusion compared to the pre-occlusion value. Values for the RHI are physiologically greater than 1 (least heal
Group
Value
95% CI
PLWH+OSA+Low LG
1.6
± .38
PLWH+OSA+High LG
1.52
± .36
Adverse events — posted to ClinicalTrials.gov
Time frame: Duration of participation in the study, which varied according to each study participant. Those subjects who were PLWH-OSA completed the study generally in 7-10 days. Subjects who were PLWH+OSA completed an additional overnight sleep study and then used CPAP therapy for 12 weeks. Their participation in the study might be up to 6 months depending on the timing of procedures..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The investigators seek to understand how the different underlying causes of OSA affect the way people living with HIV (PLWH) experience OSA. The investigators also want to understand how symptoms of obstructive sleep apnea improve with treatment, and if this too, is affected by the underlying cause of OSA in that individual
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Human Immunodeficiency Virus
Currently open trials in the same condition.
NCT07530198 — HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
· Phase 1
· recruiting
NCT06819176 — Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretrovir
· Phase 1
· recruiting
NCT06408142 — Universal Test and Connect for HIV Service Delivery in South Africa
· recruiting
NCT07101458 — The Eswatini PRISM Study on Adolescents Living With HIV
· NA
· recruiting
NCT06554223 — The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care
· NA
· recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care
· NA
· not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease
· NA
· not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes
· Phase 3
· not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples
· NA
· not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2)
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 21 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03575143.